SCHEDULE: FMR LLC Discloses 6.2% Stake in Taysha Gene Therapies

FMR LLC and its affiliates, including Abigail P. Johnson, reported a 6.2% beneficial ownership stake in Taysha Gene Therapies Inc. as of June 30, 2025.

Summary

• FMR LLC and Abigail P. Johnson, through their affiliated entities, beneficially own 15,627,821.87 shares of Taysha Gene Therapies Inc. common stock.
• This aggregate amount represents 6.2% of the total outstanding common stock of Taysha Gene Therapies Inc.
• FMR LLC holds sole voting power over 15,622,332.00 shares and sole dispositive power over 15,627,821.87 shares.
• Abigail P. Johnson is identified as a reporting person due to her role as Director, Chairman, and Chief Executive Officer of FMR LLC, and her family's predominant ownership of FMR LLC's Series B voting common shares.
• The filing indicates that while other persons may have the right to receive dividends or proceeds from these securities, no single other person's interest exceeds five percent of the total outstanding common stock.

Sentiment

Score: 5

Explanation: The filing is a factual disclosure of beneficial ownership and does not contain information that would inherently indicate a positive or negative sentiment regarding the issuer's operational or financial performance.

Positives

• NA

Negatives

• NA

Risks

• This Schedule 13G filing is a disclosure of beneficial ownership and does not detail company-specific operational or financial risks for Taysha Gene Therapies Inc.

Future Outlook

This Schedule 13G filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding Taysha Gene Therapies Inc.'s future outlook.

Industry Context

This filing represents a standard disclosure by a significant institutional investor, FMR LLC (Fidelity), regarding its passive ownership stake in a publicly traded biotechnology company. Such disclosures are routine and provide transparency into major shareholdings within the market, particularly in sectors like gene therapy where investment can be volatile and long-term focused.

Stakeholder Impact

• Shareholders may view the significant stake held by a major institutional investor like FMR LLC as a potential vote of confidence in Taysha Gene Therapies Inc., which could positively influence investor sentiment.

Key Dates

Keywords

Taysha Gene Therapies, FMR LLC, Abigail P. Johnson, Beneficial Ownership, Schedule 13G, Common Stock, Biotechnology, Investment